Research
Judy's research interests are in deciphering the interplay between signalling, transcriptional regulation, and the modification of proteins by reversible ubiquitylation, with the aim of translating discoveries as potential therapeutic approaches or biomarkers, in mesothelioma, uveal melanoma, breast or lung cancer. Her lab has been working on the discovery of BAP1-dependent therapeutic sensitivities in mesothelioma and recently developed novel chick CAM xenografts of mesothelioma cell lines and patient-derived tissues (PDX) for preclinical testing.
Roles of reversible ubiquitination in cell signalling, cell cycle and transcription.
CAM xenograft preclinical models for cancer
Translational research in mesothelioma and lung cancer
Research grants
Deubiquitinase Inhibitors as Novel Therapeutics for the Treatment of Hypoxic Lung Tumours and Mesothelioma
WORLDWIDE CANCER RESEARCH (UK)
March 2024 - February 2027
Developing a chick embryo model to aid in development of personalised therapies for malignant pleural mesothelioma
NATIONAL CENTRE FOR THE REP, REF AND RED OF ANIMALS USED IN RESEARCH (NC3RS)
November 2019 - July 2023
Integrative analysis of BAP1-dependencies to identify novel therapeutic targets for uveal melanoma: learning lessons from the lung
FIGHT FOR SIGHT (UK)
October 2019 - December 2022
Translating discovery science: DUBs that regulate centrosome clustering, an Achilles' heel of cancer
BREAST CANCER NOW (UK)
October 2019 - March 2024
Translating BAP1 dependencies for precision therapy of mesothelioma
BRITISH LUNG FOUNDATION (UK)
March 2017 - March 2021
Wellcome Trust Four-Year PhD Studentship with the Cellular and Molecular Physiology PhD Programme
WELLCOME TRUST (UK)
October 2015 - September 2019
Investigating in vivo resistance mechanisms to MEK inhibitors in uveal melanoma to enable novel combinatorial therapies.
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
March 2016 - May 2019
S18-phosphorylation controls catalytic activity of the cancer-associated deubiquitylase USP7: defining the implications for cancer biology and USP7 inhibitor therapy
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
October 2016 - December 2019